After an expedited six-month review, abiratone acetate (tradename Zytiga) has been approved by the FDA for the treatment of castration-resistant prostate cancer.
The approval comes ahead of its June 20, 2011 regulatory date due to the significant increase in overall survival shown by arbiraterone treatment. In a Phase III study, patients who received abiratone in combination with prednisone had a median overall survival of 14.8 months, compared to 10.9 for patients in the placebo group. Treatment with abiratone also resulted in a 35% reduction in the risk of death.
“While 3.9 months may not seem like much, in the history of prostate cancer, only 4 drugs have ever shown a survival benefit” said abiraterone investigator, Johann de Bono, MD., putting into perspective the apparent modest increase in survival.
The results of the trial were found by an independent panel to be so successful that it was considered unethical to keep the placebo patients without the drug. The study was stopped earlier than planned and placebo patients were crossed over to abiraterone treatment.
Abiraterone inhibits the enzyme CYP17A1 which is found in testicular, adrenal and prostate tumor tissues. The enzyme plays an important role in the production of testosterone which has been found to stimulate prostate tumor growth. Abiraterone works by ”[ultimately blocking] the cancer cell from making its own hormones” said Johann de Bono, resulting in tumor shrinkage.
Abiratone also seems promising in the treatment of breast cancer. A Phase I/II clinical trial evaluating the effectiveness of abiratone in late-state breast cancer patients is underway in the U.K.
Sources: MedScape; April 28, 2011, FDA Press Release, Investor’s Business Daily; September 24, 2010, ESMO 2010 interview by Oncology Tube: Johann de Bono, MD, GEN; September 10, 2010.
Author: Karla Robleto, Ph.D.
May 5th, 2011
Women who have experienced hot flushes and other symptoms of menopause may have a 50 percent lower risk of developing the most common forms of breast cancer than postmenopausal women who have never had such symptoms, according to a recent study.
Continue Reading
March 8th, 2011
|
Former Fremonter writes articles, blogs and a book on fatherhoodFremont TribuneFive years ago, Higley, then 44, was diagnosed with early stage prostate cancer. "They caught it by accident. I had zero symptoms," he said, adding, "I was extremely lucky. My oncologist and surgeon said I probably would have been dead within a year …
|
Continue Reading
March 5th, 2011
A quarter of all women who suffer from breast cancer are at risk of metastasis – a recurrence of the cancer. In recent years, researchers have developed a technique that can identify in advance which patients belong to this risk group. Within the next two years the method will be tested in Swedish hospitals. In the future, the technique may also be used in hospitals in other countries.
Continue Reading
March 4th, 2011
New findings confirm the risk of breast cancer among women who are obese and not physically active, and suggests additional mechanisms beyond estrogen.
Continue Reading
March 3rd, 2011
Between 5 and 10 percent of breast cancer cases are hereditary, arising because the patient inherits from the father or mother a mutation in a gene that is susceptible to causing the illness. BRCA1 and BRCA2 have already been identified as two of the genes to be monitored. It is estimated that 30 percent of hereditary breast cancer cases are due to mutations in one of these two genes (which suggests, at the same time, that there are other genes involved, but exactly how is still unknown). In any case, few of the mutations found in BRCA1 and BRCA2 could be clearly identified as pathological. The fact is that the mutations found were numerous; their variation even depending on the population.
Continue Reading
March 1st, 2011
Obese women may avoid mammograms because of pain and women under 60 may avoid the test because they are too busy, according to a new study.
Continue Reading
March 1st, 2011
Researchers have discovered that resveratrol — a compound found in red wine — when combined with rapamycin can have a tumor-suppressing effect on breast cancer cells that are resistant to rapamycin alone. The research also indicates that the PTEN tumor-suppressing gene contributes to resveratrol’s anti-tumor effects in this treatment combination.
Continue Reading
February 28th, 2011
Ductal carcinoma in situ, or non-invasive breast cancer, is typically treated with either breast-conserving surgery — with or without follow-up radiation — or mastectomy. The treatment choice depends on clinical factors, the treating surgeon, and patient preferences. Long-term health outcomes (disease-free survival) depend on the treatments received. According to a new study, however, health outcomes also are associated with the treating surgeon.
Continue Reading
February 28th, 2011
Doctors are calling for women to receive more information about the pitfalls of breast cancer screening, as well as the benefits, after some women who received false-positive results faced serious anxiety and reduced quality of life for at least a year. The study of 385 women found that the 233 with false-positive results – where the mammogram is abnormal but no cancer is present – had to undergo more diagnostic procedures than women with breast cancer before they were given the all clear. And women who had a tendency to be anxious fared much worse if they received a false-positive – estimated to happen in 60% of abnormal mammograms – than if they were actually diagnosed with breast cancer.
Continue Reading
February 27th, 2011
Previous Posts
